- NEWS
- Correction 07 July 2021
- Correction 08 July 2021
Russia’s vaccine is in use in nearly 70 nations, but its adoption has been slowed by controversies and questions over rare side effects, and it has yet to garner World Health Organization approval.
Russia’s COVID-19 vaccine, Sputnik, has been the subject of fascination and controversy since the Russian government authorized its use last year, before early-stage trial results were even published. Evidence from Russia and many other countries now suggests it is safe and effective — but questions remain about the quality of surveillance for possible rare side effects.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 595, 339-340 (2021)
doi: https://doi.org/10.1038/d41586-021-01813-2
Updates & Corrections
-
Correction 07 July 2021: An earlier version of this story stated incorrectly that an analysis of 2.8 million doses that reported no deaths took place in Brazil. In fact, it was in Argentina. The text has been updated.
-
Correction 08 July 2021: An earlier version of this story used the figure for the number of adults randomized to the two doses of placebo in the phase III trial, instead of the figure for the number of adults who actually received two doses of placebo in that trial. That figure has been updated.
References
Logunov, D. Y. et al. Lancet 397, 671–681 (2021).
Logunov, D. Y. et al. Lancet 396, 887–897 (2020).
Pagotto, V. et al. Preprint at medRxiv https://doi.org/10.1101/2021.02.03.21251071 (2021).
Montalti, M. et al. Preprint at medRxiv https://doi.org/10.1101/2021.05.03.21256509 (2021).
Related Articles
-
Six months of COVID vaccines: what 1.7 billion doses have taught scientists
-
China’s COVID vaccines are going global — but questions remain
-
Researchers highlight ‘questionable’ data in Russian coronavirus vaccine trial results
Can Cuba beat COVID with its homegrown vaccines?